Aim: To raise awareness on nocturia disease burden and to provide simplified aetiologic evaluation and related treatment pathways.
termsofdirect(fallsandfractures),indirect(decreasedworkproductivity andactivitylevels)andintangiblecosts(reductioninQoL). 5, 14 Althoughverycommon,nocturiaremainsanunderreported,undertreated and poorly managed medical and social problem in adults. 15, 16 Nocturia was oftentimes considered a symptom associated with functional issues, such as overactive bladder syndrome (OAB) and/or benignprostatichyperplasia(BPH),withtreatmentsfocusedonincreasing bladder capacity and/or lowering bladder outlet obstruction. However, because nocturia is often associated with nocturnal polyuria-the overproduction of urine during the night-such treatments will not be effective for all patients and appropriate patient selection is essential. [17] [18] [19] As such, it is essential that physicians and other healthcare professionals understand the aetiology, burden and the most effective methods for diagnosing, assessing and treating nocturia. The treatment of nocturia should be according to its causative factors and aetiology where possible,asrecommendedintheEuropeanAssociationofUrologyguidelines onthetreatmentofmaleLUTS 20 ; however, specific guidelines for nocturia have not yet been published as a journal article.
| Aim
Theaimofthisexpertpaperwastoraiseawarenessandincreaserecognition of nocturia as a medical condition and provide straightforward, practical recommendations for its diagnosis and management. 
| METHODS

| RESULTS AND DISCUSSION
| Terminology
In2002,theICSdefinednocturiaasthe need to void one or more times during the night, with each void preceded and followed by sleep. 1, 2 This definition is currently a topic of debate 21, 22 ; however, nocturia often only becomes clinically relevant when it causes comorbidities or bother for the patient. Nocturia once per night has been reported to occurinupto18.2%ofhealthywomenaged18-30years,butwith low associated bother to the individual. 23 A more clinically relevant definitionofnocturiais"≥2voidspernight,"asatthispointitwould become bothersome for most individuals. 13, 24 It should be recognised, 
| Epidemiology of nocturia
Nocturia is one of the most bothersome LUTS according to most epidemiological studies. 7, 25, 26 The prevalence of nocturia is high and broadlysimilarinmenandwomen,affecting28%-93%ofthoseaged 40 years or older. [27] [28] [29] The prevalence varies depending on the definition (from 1 to 3 voids per night). A review of 43 epidemiological studiesreportedprevalenceratesof11%-35%for≥1voidpernight and2%-17%for≥2voidspernightformenaged20-40years,whilst forwomeninthesameagegroup,ratesof20%-44%for≥1voidper nightand4%-18%for≥2voidspernightwerereported. 27 The prevalence of nocturia in the community increases with age, with rates of 29%-59%formenaged70-80yearsandof28%-62%forwomenof thesameage(≥2voidspernight). 27 Other studies have reported rates
and34%formenand28%forwomen(>2voidspernight) aged over 40 years. 28 Inanotherstudy,reportingaprevalenceof34%
inwomenaged>40years,itwasfoundthat40%ofthosewithnoc-turia had no other urinary tract symptom. 26 In terms of incidence, a recent meta-analysis of 13 studies reportedarateof0.4%peryearamongadults(menandwomen)aged <40years,2.8%peryearamongthoseaged40-59yearsand11.5%
peryearamongthoseaged≥60years(≥1voidpernight). 
| Evaluating patients with nocturia
Numerous underlying factors may contribute to nocturia, and one or several of these factors may be present in an individual (eg, nocturnal
What's known
• Anon-systematicreviewoftherelevantliteraturewasundertaken,supplementedbystudiesidentifiedbytheauthors. 
| Risk factors and comorbidities
Nocturia (≥2 voids per night) has been significantly associated with various risk factors and comorbidities (Table1).
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Several epidemiological studies have also reported a positive association between nocturia and erectile dysfunction in diabetic 42 and non-diabetic men. 
| Impact of nocturia
Nocturia can have a significant, negative impact on patients' QoL (both mental and physical) and be linked to depression and increased mortality. 5,6,9,13,29 TheimpactonQoLcomesprimarilyfrom disturbed sleep caused by nocturia, which can lead to sleep deprivation, especially when there is difficulty in returning to sleep. 5, 10 This leads to tiredness and daytime fatigue that can affect daily activitiesandtherebyreduceQoL. 5, 10 Nocturnal voiding can negatively affect the occurrence and length of deep, restorative (N3) sleep, often considered the most restorative stage of sleep. 44 Longterm loss of N3 sleep as occurs in nocturia could have potentially deleterious impact on daytime alertness, health and well-being. 44, 45 The negative effect of nocturia on sleep outcomes appears to be stronger in adults aged >65 years. 46 Asnocturiacausesactivityat nightwhenapatientmaynotbefullyawake,itisalsoanimportant cause of falls and fall-related fractures in the elderly population.
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A population-based epidemiologic survey also found a strong association of nocturia with depression in both men and women, with a significant trend in increased odds of depression with more voids nightly. 13 The magnitude of this association was larger in younger age groups, especially among women aged <50 years. 48 The impact of nocturia has considerable pecuniary implications for patients and the health service. It was estimated that hospitalisations acrosstheEUduetohipfracturesassociatedwithnocturiacostapproximately€1.0billionin2014. 5 In addition to these direct costs, indirectcostsarisefromdecreasedworkproductivityandactivitylevels, withlostproductivityatworkintheEUregionin2014duetonocturia estimated to have cost €29.0 billion. 5 In the USA, the annual direct costs due to nocturia-associated fallswere estimated to be approximately $1.5 billion and the indirect costswere expected to be $61 billion in 2014. 
| Clinical presentation and evaluation
Many patients may not recognise nocturia as a medical condition amenable to treatment or they may be embarrassed or reluctant to discuss symptoms, 15, 49, 50 so there is an onus on the physician to broach the topic to avoid delays in diagnosis and treatment. 51 In one survey, in which prevented them from seeking treatment. 15 Of those women whohadconsultedadoctor,37.2%werenotofferedanytreatment. 15 In another population-based study of 8659 patients, it was reported thatittook,onaverage,51weeksforthepatienttohaveafirstcon-sultationaftertheonsetofnocturia,withafurther12weekstomake
adiagnosis,andanother37weeksfromdiagnosisuntilfirstprescribed treatment. 16 The overall time from the onset of symptoms to beginningtreatmentwasnearly2years(mean105.5weeks). 16 In this study, themostcommonreasonforseekingmedicalhelpwasworseningof symptoms (severity or frequency). Urinary incontinence, tiredness, fearofother(serious)underlyingdiseasesandrecommendationofa friend or relative were other important reasons to consult a doctor. 16 This study implied that there should be greater awareness and screening for nocturia, even in the absence of other urinary symptoms. 36 FVCs also help to target specific non-urologic aetiologies. 33 Use of a screening tool, such as the recently published TANGO(Targetingtheindividual'sAetiologytoGuideOutcomes), 57, 58 can also potentially aid in the identification and assessment of nonlowerurinarytractcomorbiditiesassociatedwithnocturia.FVCscan be supplemented by bladder diaries, which are especially useful in compliant patients over longer stretches of time and provide an opportunity for patients to add important qualitative details about or associated with their symptoms. 59 FVCsorbladderdiariesshouldbe completed for a minimum of 3 days, and it is important that the need foraccuracyisexplainedtothepatientbeforeaskingthemtocomplete it. 60, 61 These self-monitoring approaches also aim to reflect and educatepatientsonthecorrectuseortimingoffluidintakeinmanaging nocturia. • Urinalysis(bydipstickorurinarysediment)andmeasurement of postvoid residual volume should be performed in all cases and followed up with additional tests (eg, uroflowmetry, computer-urodynamic evaluation of bladder function and cystoscopy,etc)aswarranted.
| Treatment of nocturia
• Diagnosis of nocturia and nocturnal polyuria should be based ontheresultsofaFVCandsubsequentinvestigationstodiscriminate among the potential underlying causes of nocturia (Figure1).
• FVCsmaybesupplementedbybladderdiaries.
• The patient should be referred to the relevant specialty within secondary care for further investigation (if the primarycause(s)remainunclearortoocomplicatedtotreat). 
T A B L E 2 Assessmentofpatientswithnocturia
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Increased diuresis
Desmopressin, a synthetic vasopressin analogue, acts on the V 2 receptors of the distal collecting tubules with the aim of concentrating urine at night. 33 TreatmentwithaV 2 agonist is useful only in patients with idiopathic nocturnal polyuria with excessive water diuresis, or in patients with central diabetes insipidus, as this is indicative of suppressed vasopressin levels. 40 However, where there is nocturnal sodium diuresis, treatment to restore a normal sodium clearance
).*Somepatientsmightnotrequire referraltoacardiologist.TheNationalInstituteforHealthandCareExcellence(NICE)guidelinesforchronicheartfailurestatethatreferralof patients to a cardiologist is only necessary for initial diagnosis and patients with severe heart failure or where the condition is not responding to treatment serum half-life of around 2.8 hours, meaning that its effect lasts for approximately8hours. 78 Aonce-daily,low-dose,gender-specificformulation of desmopressin has lately become available: 25 μg for women and 50 μg for men. 79 This formulation has the benefit of reducing the antidiuretic activity to a maximum of 3-5hours during the nightly sleep, 79 whilst also limiting the risk of hyponatraemia, an adverse event associated with higher doses of desmopressin. 67 Desmopressin shouldbetakenonehourbeforegoingtobed(withtheintentionof sleeping)withoutwater(formeltorspray)orwithminimalwater(for tablet)andwithfluidrestrictedtoaminimumuntileighthoursafter dosing; otherwise, fluid retention and/or hyponatraemia may result. 79 Comparison of 25 μg desmopressin once daily to placebo in 261 womenwithnocturia(≥2voidspernight)foundthatdesmopressinsignificantly reduced the mean number of nocturnal voids and increased the mean time to first nocturnal void by 49 minutes compared with placebo at 3 months. 67 Similar efficacy has been demonstrated in a study that investigated 50 and 75 μgdesmopressininmenwithnocturia(≥2voids pernight). 68 Significantincreasesinhealth-relatedQoLandundisturbed sleep were also observed compared with placebo. 45, 68 A further study from Japan evaluating four different doses of orally disintegrating sublingualdesmopressin(10,25,50or100 μg)suggestedthatwomanappear Nocturia often improves in patients with OSA using continuous positive airway pressure. 41 Patients who undergo uvulopalatopharyngoplastyfortheirOSAhavealsoseenanimprovementinnocturia symptoms.
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Recommendations on the treatment of nocturia
• Treatment should be tailored to the cause(s) of nocturia in the individual patient.
• Some medications can precipitate nocturia and, therefore, change of the drug or timing of drug use may be warranted.
• Lifestyle and behavioural modifications should be attempted before instigating other treatments, with a trial of up to 3 months, a reasonable time period over which to assess treatment response, unless bother is increasing and intolerable.
• Pharmacological therapies should be introduced after lifestyle modifications have failed or as adjuncts.
• Patientsondiuretictherapyshouldtakediureticsduringthe mid-lateafternoon,takingintoconsiderationthehalf-lifeof the specific agent.
• Desmopressin is the pharmacologic treatment for nocturia duetonocturnalpolyuriawiththehighestqualityevidence to support its use, with a once-daily, low-dose, gender-specific formulation indicated for nocturia due to nocturnal polyuria.
• Diuretics, α1-blockers,5α-reductaseinhibitors,PDE5i,plant extracts, antimuscarinics and the β3-agonist mirabegron all havepotentialutilitytoreducenocturnalvoidingfrequency in patients with different causes of decreased functional bladder capacity, although the clinical impact of such treatments appears to be limited.
• Educating patients on the available treatment options and involving them in the decision-making process can help to increase adherence to medication and thereby improve patientfunctioningandQoL. 87 • After implementing therapy, its efficacy and effect on patients should be assessed, with consideration given to combiningtherapies/interventionsinthelightofaninadequate response.
• Patients with nocturia of undetermined cause not responding to lifestyle and medical therapy should be considered for specialist assessment. 
| CONCLUSIONS
